富祥药业（300497）披露控股孙公司完成注册登记公告，2月4日股价下跌0.59%

Core Viewpoint - Fujian Pharmaceutical (300497) is expanding its business into the European alternative protein market through a joint venture in Slovenia, aiming to leverage EU market access advantages and enhance its global business network [1]. Group 1: Company Overview - As of February 4, 2026, Fujian Pharmaceutical's stock closed at 15.19 yuan, down 0.59% from the previous trading day, with a total market capitalization of 8.182 billion yuan [1]. - The stock opened at 15.2 yuan, reached a high of 15.34 yuan, and a low of 14.98 yuan, with a trading volume of 1.81 billion yuan and a turnover rate of 2.71% [1]. Group 2: Recent Developments - Fujian Pharmaceutical announced the completion of the registration of its controlling subsidiary, Jiangxi Fujian Pharmaceutical Co., Ltd., which established a joint venture named Myco One d.o.o. in Slovenia with a registered capital of 300,000 euros, where Fujian holds a 51% stake [1]. - The joint venture will focus on the research, development, production, and sales of alternative protein products, specifically targeting applications in plant-based meat, protein beverages, baked goods, and pet food [1]. - The investment aims to transition the alternative protein business from raw materials to end-brand products and to build a global business network, utilizing the partner's channels to penetrate mainstream supermarket systems [1].